These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 1699068)
1. [A dynamic cytologic study during the chemotherapy of cancer of the ovaries]. Iakimova TP; Iakovtsova II; Samsonova LA; Skripnik LD; Pavlova TD Lab Delo; 1990; (7):42-4. PubMed ID: 1699068 [TBL] [Abstract][Full Text] [Related]
2. A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration. Ohtani K; Sakamoto H; Masaoka N; Shimada K; Kanaeda T; Kurihara M; Nagai N; Satoh K Gynecol Oncol; 2000 Dec; 79(3):515-8. PubMed ID: 11104632 [TBL] [Abstract][Full Text] [Related]
3. [Advanced ovarian cancer with Sister Mary Joseph's nodule--a case report]. Ohta S; Yamakawa Y; Hasegawa T; Tateno M; Matsui K Gan To Kagaku Ryoho; 2007 Jan; 34(1):117-9. PubMed ID: 17220685 [TBL] [Abstract][Full Text] [Related]
4. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148 [TBL] [Abstract][Full Text] [Related]
5. [Adjuvant chemotherapy in primary radically operated ovarian cancer]. Illiger HJ; del Valle F; Mühlenstedt D Onkologie; 1985 Oct; 8(5):316, 321-3. PubMed ID: 3906479 [TBL] [Abstract][Full Text] [Related]
6. Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Le T; Williams K; Senterman M; Hopkins L; Faught W; Fung-Kee-Fung M Ann Surg Oncol; 2007 Sep; 14(9):2649-53. PubMed ID: 17562112 [TBL] [Abstract][Full Text] [Related]
7. [Cytologic study in assessing the effectiveness of chemotherapy in patients with ovarian cancer]. Korop AG; Genes IS; Ronin VS; Kartavenko NB; Pavlova TD; Ordzhonikidze NF Lab Delo; 1989; (9):49-51. PubMed ID: 2481133 [TBL] [Abstract][Full Text] [Related]
8. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary. Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213 [TBL] [Abstract][Full Text] [Related]
9. [Adjuvant chemotherapy of cancer of the ovary]. Cappelaere P; Horner-Vallet D; Demaille A Bull Cancer; 1984; 71(4):363-9. PubMed ID: 6498348 [TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S; J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and tumoral markers in ovarian carcinoma. Francioni S; Pastore M; Fornara G J Nucl Med Allied Sci; 1989; 33(3 Suppl):111-3. PubMed ID: 2480407 [TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer. Lan C; Li Y; Liu J Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124 [TBL] [Abstract][Full Text] [Related]
13. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities]. du Bois A; Lück HJ; Meerpohl HG Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970 [TBL] [Abstract][Full Text] [Related]
14. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296 [TBL] [Abstract][Full Text] [Related]
15. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839 [TBL] [Abstract][Full Text] [Related]
16. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Silva EG; Gershenson DM; Malpica A; Deavers M Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075 [TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of prognostic factors for stage III ovarian epithelial carcinoma]. Wu M; Shen K; Lang JH; Huang RL; Huang HF; Pan LY Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1406-9. PubMed ID: 16029654 [TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153 [TBL] [Abstract][Full Text] [Related]
19. Current status of chemotherapy in gynecologic cancer. Tropé C; Kristensen G Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-1-S15-22. PubMed ID: 9346216 [No Abstract] [Full Text] [Related]
20. [Tolerance induction in anaphylaxis to carboplatin]. Herzinger T; Behr J; Przybilla B Dtsch Med Wochenschr; 2003 Jul; 128(30):1595-6. PubMed ID: 12884147 [No Abstract] [Full Text] [Related] [Next] [New Search]